Recent performance context for Elevance Health

With no single headline event driving attention today, Elevance Health (ELV) is drawing interest as investors weigh its recent share price performance against current earnings, revenue and value indicators across its health benefits and pharmacy services operations.

The recent pullback, including a 12.66% 1 month share price return decline and a 15.15% 1 year total shareholder return decline, points to fading momentum as investors reassess Elevance Health relative to its earnings, cash generation and valuation metrics.

If this cautious tone around Elevance Health has you thinking about where growth and innovation might show up next in healthcare, take a look at our screener of 27 healthcare AI stocks as a starting point for fresh ideas.

With Elevance Health trading below its indicated price target and sitting on recent share price declines, investors may question whether this weakness points to undervaluation or whether the market is already pricing in the company’s future growth.

Most Popular Narrative: 16.6% Undervalued

According to NateF, the most followed narrative pegs Elevance Health's fair value at $390.54, comfortably above the last close at $325.64, which puts a spotlight on the gap between narrative pricing and where the market is currently trading.

Elevance Health’s investment potential over the next 1-3 years lies in balancing risks associated with Medicaid declines, cost management, and regulatory uncertainties against growth opportunities in Medicare Advantage, value-based care, and digital health innovation. Its established market position and diversified portfolio provide resilience, but operational cost pressures and policy changes will be critical factors influencing performance.

Curious what sits underneath that fair value of $390.54? This narrative leans heavily on assessments of future earnings power, margin recovery and how much growth Medicare Advantage and value based care can realistically carry. If you want the full picture on those assumptions and how they compare with the current share price, the rest of the narrative joins the dots.

Result: Fair Value of $390.54 (UNDERVALUED)

However, this depends on cost and Medicaid pressures easing, and any prolonged squeeze on margins or lower than expected earnings could quickly challenge that undervaluation story.

Build Your Own Elevance Health Narrative

If this view does not quite fit how you see Elevance Health, or you simply prefer to weigh the numbers yourself, you can build a tailored view in just a few minutes and Do it your way.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Elevance Health.

Looking for more investment ideas?

If Elevance Health has you thinking more broadly about your portfolio, now is a good time to widen your watchlist with a few focused stock shortlists.

• Target resilient companies first by scanning our 83 resilient stocks with low risk scores to help you focus on businesses with steadier risk profiles.
• Hunt for quality at a reasonable price by reviewing our 51 high quality undervalued stocks to spot stocks that may trade below their indicated worth.
• Spot tomorrow's stories early by checking our screener containing 24 high quality undiscovered gems highlighting lesser known names with solid underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.